Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sometimes too much of a good thing is not good at all. Inhibiting the function of the PD-1 protein, which blocks immune function, has shown high therapeutic efficacy in cancer immunotherapy.
GSK is partnering with Mersana Therapeutics on the development of an antibody-drug conjugate that is approaching Phase 1 testing. Unlike other ADCs that deliver a toxic drug payload, the Mersana drug is designed to activate the innate immune system to fight tumor cells.
During a battle with cancer, T cells can become exhausted and are no longer able to function properly. The early phase of exhaustion can sometimes be reversed with immunotherapy drugs, but once T cells become too exhausted, it had been thought that this state was irreversible. However, new insights from University of Pittsburgh and UPMC researchers suggest that even the most fatigued T cells can be revived.
1. Early life acquisition of AMR in newborn children from low and middle-income countriesIn a new study published in Nature Microbiology, Dr. Maria Carvalho, Dr. Kirsty Sands and a network of ...
Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy.